RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development.

Blood vessel formation is a complex morphological process that is only beginning to be understood at the molecular level. In this study, we demonstrate a novel and critical role for the small GTPase, RhoB, in vascular development. RhoB null mice have retarded vascular development in the retina characterized by altered sprout morphology. Moreover, pharmaceutical means to deplete RhoB in neonatal rats is associated with apoptosis in the sprouting endothelial cells of newly forming vessels. Similarly, acute depletion of RhoB by antisense or dominant-negative strategies in primary endothelial cell culture models led to apoptosis and failures in tube formation. We identified a novel link between RhoB and the Akt survival signaling pathway to explain these changes. Confocal microscopy revealed that RhoB is highly localized to the nuclear margin with a small percentage found inside the nucleus. Similarly, total Akt is throughout the cell but has increased accumulation at the nuclear margin, and active phosphorylated Akt is found primarily inside the nucleoplasm, where it partially colocalizes with the RhoB therein. We show that this colocalization is functionally relevant, because when RhoB was depleted, Akt was excluded from the nucleus and total cellular Akt protein was decreased in a proteosome-dependent manner. Because the function of RhoB in vivo appears to only be rate limiting for endothelial cell sprouting, we propose that RhoB has a novel stage-specific function to regulate endothelial cell survival during vascular development. RhoB may offer a therapeutic target in diseases such as cancer, diabetic retinopathy, and macular degeneration, where the disruption of sprouting angiogenesis would be desirable.

[1]  M. Aepfelbacher,et al.  Bacterial toxins block endothelial wound repair. Evidence that Rho GTPases control cytoskeletal rearrangements in migrating endothelial cells. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[2]  W. Sessa,et al.  Regulation of endothelium-derived nitric oxide production by the protein kinase Akt , 1999, Nature.

[3]  G. Prendergast,et al.  Functional interaction between RhoB and the transcription factor DB1. , 1998, Cell adhesion and communication.

[4]  J. E. Griffiths,et al.  The Akt kinase signals directly to endothelial nitric oxide synthase , 1999, Current Biology.

[5]  J. Stone,et al.  Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.

[6]  G. Prendergast,et al.  Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. , 2000, Seminars in cancer biology.

[7]  A. Zeiher,et al.  Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[8]  G. Garcı́a-Cardeña,et al.  Distinct Mechanical Stimuli Differentially Regulate the PI3K/Akt Survival Pathway in Endothelial Cells , 2000, Annals of the New York Academy of Sciences.

[9]  P. Cohen,et al.  Role of Translocation in the Activation and Function of Protein Kinase B* , 1997, The Journal of Biological Chemistry.

[10]  D. Coppola,et al.  The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis , 2000, Molecular and Cellular Biology.

[11]  G. Prendergast,et al.  Actin' up: RhoB in cancer and apoptosis , 2001, Nature Reviews Cancer.

[12]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[13]  G. Prendergast,et al.  Farnesyltransferase inhibitors: mechanism and applications , 2001, Expert opinion on investigational drugs.

[14]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[15]  Vishva Dixit,et al.  Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway , 1998, The Journal of Biological Chemistry.

[16]  M. Detmar,et al.  A simple immunomagnetic protocol for the selective isolation and long-term culture of human dermal microvascular endothelial cells. , 1998, Experimental cell research.

[17]  E Ruoslahti,et al.  Integrins and anoikis. , 1997, Current opinion in cell biology.

[18]  Y. Fujio,et al.  Akt Mediates Cytoprotection of Endothelial Cells by Vascular Endothelial Growth Factor in an Anchorage-dependent Manner* , 1999, The Journal of Biological Chemistry.

[19]  P. Adamson,et al.  Intracellular localization of the P21rho proteins , 1992, The Journal of cell biology.

[20]  G. Prendergast,et al.  Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity , 1995, Molecular and cellular biology.

[21]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[22]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[23]  Michael B. Yaffe,et al.  14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport , 2002, The Journal of cell biology.

[24]  A. Copp,et al.  RhoB is expressed in migrating neural crest and endocardial cushions of the developing mouse embryo , 2000, Mechanisms of Development.

[25]  David Michaelson,et al.  Differential Localization of Rho Gtpases in Live Cells , 2001, The Journal of cell biology.

[26]  P. Parker,et al.  Regulation of epidermal growth factor receptor traffic by the small GTPase RhoB , 1999, Current Biology.

[27]  Mark A Sussman,et al.  Myocardial Akt Activation and Gender: Increased Nuclear Activity in Females Versus Males , 2001, Circulation research.

[28]  A. Kral,et al.  Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice , 1995, Nature Medicine.

[29]  T. Jessell,et al.  RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors , 2000, Molecular and Cellular Biology.

[30]  G. Zalcman,et al.  Regulation of Ras-related RhoB protein expression during the cell cycle. , 1995, Oncogene.

[31]  N. Ferrara VEGF: an update on biological and therapeutic aspects. , 2000, Current opinion in biotechnology.

[32]  I. Buschmann,et al.  Arteriogenesis, the good and bad of it. , 1999, European heart journal.

[33]  J. Kim,et al.  Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. , 2000, Circulation research.

[34]  P. Casey,et al.  Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB* , 1997, The Journal of Biological Chemistry.

[35]  Channing J Der,et al.  Farnesyltransferase inhibitors: promises and realities. , 2002, Current opinion in pharmacology.

[36]  S. R. Datta,et al.  Transcription-dependent and -independent control of neuronal survival by the PI3K–Akt signaling pathway , 2001, Current Opinion in Neurobiology.

[37]  P. Carmeliet,et al.  Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis , 1999, Cell.

[38]  G. Prendergast,et al.  Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors , 2003, Oncogene.

[39]  T. Byzova,et al.  A mechanism for modulation of cellular responses to VEGF: activation of the integrins. , 2000, Molecular cell.

[40]  A. Ridley Rho Proteins: Linking Signaling with Membrane Trafficking , 2001, Traffic.

[41]  G. Prendergast,et al.  Geranylgeranylated RhoB is sufficient to mediate tissue‐specific suppression of Akt kinase activity by farnesyltransferase inhibitors , 2000, FEBS letters.

[42]  L. Aiello,et al.  Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. , 1999, Diabetes.

[43]  P. Morcos Achieving efficient delivery of morpholino oligos in cultured cells , 2001, Genesis.

[44]  C. Thompson,et al.  Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. , 2002, Molecular biology of the cell.

[45]  A. Zeiher,et al.  Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. , 1998, Circulation research.

[46]  G. Prendergast,et al.  Non-Ras targets of farnesyltransferase inhibitors: focus on Rho , 1998, Oncogene.